Artia Global Partners LP Has $13.28 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Artia Global Partners LP boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 112.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 162,255 shares of the company's stock after buying an additional 86,000 shares during the quarter. Vaxcyte makes up about 4.7% of Artia Global Partners LP's investment portfolio, making the stock its 6th largest position. Artia Global Partners LP owned 0.13% of Vaxcyte worth $13,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. CIBC Asset Management Inc grew its holdings in shares of Vaxcyte by 5.5% in the 4th quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock worth $271,000 after purchasing an additional 171 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares in the last quarter. Catalyst Funds Management Pty Ltd grew its stake in Vaxcyte by 1.7% during the fourth quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after buying an additional 300 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the fourth quarter worth approximately $28,000. Finally, Blue Trust Inc. raised its stake in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after acquiring an additional 371 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of recent analyst reports. Bank of America dropped their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Cantor Fitzgerald began coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating for the company. The Goldman Sachs Group reduced their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, Guggenheim reissued a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $136.50.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $86.22, for a total transaction of $689,760.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at $17,735,022.90. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 24,000 shares of company stock valued at $1,946,720. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Trading Down 1.7 %

Shares of PCVX traded down $0.60 on Thursday, reaching $35.24. 3,845,146 shares of the company's stock were exchanged, compared to its average volume of 1,253,450. The business has a 50 day moving average price of $52.73 and a two-hundred day moving average price of $78.72. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The stock has a market capitalization of $4.54 billion, a P/E ratio of -7.66 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. Equities research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.